Skip to main content

Author: The Wistar Institute

Wistar’s Biomedical Technical Training Program Featured on Fox 29 Good Day Philadelphia

The Wistar Institute’s Biomedical Technical Training (BTT) Program was recently featured on Fox 29’s Good Day Philadelphia. Dr. Kristy Shuda McGuire, Dean of Biomedical Studies, and 2022 Program graduate Tylier Driscoll, discussed the history of the training program and Tylier’s experience as a participant. For more than 20 years, the BTT pre-apprenticeship has helped to prepare community college students for positions in biomedical science labs. The Program has recently expanded to reach even more students in the region. Following his completion of the BTT Program, Tylier was hired by BioAnalysis, LLC, a Philadelphia-based contract research organization (CRO).

View the full interview.

Mohamed Abdel-Mohsen, Ph.D.

Mohamed Abdel-Mohsen, Ph.D.

Associate Professor, Vaccine & Immunotherapy Center

Abdel-Mohsen’s research focuses on understanding the role of host glycosylation machinery in viral persistence and immunopathogenesis.

Abdel-Mohsen joined The Wistar Institute as Assistant Professor in 2017 after completing his Ph.D. and postdoctoral training at the University of California, San Francisco (UCSF) and the Blood Systems Research Institute (BSRI), where he was subsequently appointed as a research scientist. Previously, he was a virologist for the World Health Organization Regional Reference Laboratory for poliovirus in his home country of Egypt. He received the UCSF-Gladstone CFAR Early-Career Award of Excellence in Basic Science in 2015.

View Publications

The Abdel-Mohsen Laboratory

215-898-6008

mmohsen@wistar.org

The Abdel-Mohsen Laboratory

Recent advances in the emerging field of glycoimmunology show that the human glycome is not just a biomarker of biological functions but also plays critical roles in driving or modulating immune responses, and in cell-cell and cell-pathogen interactions. The new knowledge from glycoscience may allow us to leverage advances in the human genome and proteome to realize the goals of personalized medicine.

Our recent discoveries and publications have shown that host glycosylation—a previously unappreciated factor—impacts chronic inflammation and viral persistence during HIV infection. These studies set the stage for broader-scale studies to understand the upstream mechanisms and downstream consequences of our observations and to design novel strategies to manipulate glycosylation to reduce viral persistence and/or prevent or delay the development of viral-associated co-morbidities.

This research has the potential to expand the boundaries of current knowledge about the link between infections, chronic inflammation, and the development of chronic diseases, and will be important not just for HIV, but for other diseases involving inflammation, autoimmune disorders, cancer, and pathogen infections.

Staff

Available Positions

A postdoctoral fellow position is available in the lab. Motivated candidates are encouraged to contact mmohsen@wistar.org.

Research

Glycoimmunology is an emerging field focused on understanding how immune responses are mediated by glycans (carbohydrates) and their interaction with glycan-binding proteins called lectins. How glycans influence immunological functions is increasingly well understood. In parallel, research in the HIV field is unveiling how the host immune system controls HIV persistence and immunopathogenesis. However, the role played by the host glycosylation machinery in modulating the persistence and immunopathogenesis of HIV has mostly been overlooked despite its potential for therapeutic applications.

Our laboratory is using several advanced glycomic technologies to investigate the role of the host glycosylation machinery in regulating molecular mechanisms central to HIV infection. We aim to create a new paradigm for discovering novel biomarkers of viral/host interactions and/or glycan-based interactions that can be therapeutically targeted to cure HIV and/or enhance the quality of life for people living with it. We believe that our research has the potential to expand the boundaries of current knowledge about the link between infections, chronic inflammation and the development of chronic diseases. This information will be important not just for HIV, but for other diseases involving inflammation, autoimmune disorders, cancer, and pathogen infections.

Below, we illustrate four areas in which the links between glycan-lectin interactions and immunology, and between immunology and HIV are described. Our laboratory is investigating the links between glycoimmunology and HIV persistence/immunopathogenesis within these areas.

  • Complete Illustration

    Illustration of the four areas in which the links between glycan-lectin interactions and immunology, and between immunology and HIV are described. Our laboratory is investigating the links between glycoimmunology and HIV persistence/immunopathogenesis within these areas.

    Download Image

  • Circulating Glycomes Mediate Inflammatory Responses

    Chronic inflammation has been associated with aberrant IgG glycosylation patterns and is prevalent in HIV+ individuals despite antiretroviral therapy (ART). Sialylated and galactosylated glycans have been associated with anti-inflammatory responses while bisected N-acetylglucosamine (GlcNAc) has been associated with pro-inflammatory responses. HIV infection causes pro-inflammatory changes, e.g., ART-irreversible loss of sialic acid and ART-reversible loss of galactose. Whether the HIV-induced changes in the circulating glycome are linked to chronic inflammation and HIV-associated co-morbidities (such as cardiovascular diseases and neurological impairments) is not clear. Asn = Asparagine.

  • IgG Glycosylation Mediates Antibody-Dependent Effector Functions

    Antibody-mediated effector functions are significantly affected by changes in IgG glycosylation and are important for preventing and controlling HIV infection. The presence of core fucose reduces antibody-dependent cellular cytotoxicity (ADCC), and the presence of galactose induces ADCC, antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). The size of the HIV reservoir, measured using nucleic acid-based methods (CD4+ T cell-associated HIV DNA and RNA), negatively associates with levels of non-fucosylated galactosylated glycans during suppressive ART. However, it is not clear if the documented roles of non-fucosylated galactosylated glycans in promoting ADCC and ADCP impact viral control during ART. C1q = Complement component 1q.

  • Host Glycomic Regulation of the Gut Microbiota

    The potential role of the gut glycome in regulating the homeostatic relationship between the host and its gut microbiota during HIV infection. The potential role of the gut glycome in regulating the homeostatic relationship between the host and its gut microbiota, during HIV infection. The degree of glycosylation in the gut directly impacts the ability to maintain functional and healthy intestines. Here we give one example, by illustrating the role of gut fucosylation in the host-microbe interplay. Fucosylated glycans in the gut (left) enhance the beneficial activity of symbionts and improve resistance against colonization by pathogens and pathobionts. In the absence of gut fucosylation (right), beneficial symbionts are weakened and decreased in abundance, and pathogenic bacteria increase, which leads to microbial translocation, inflammation, and breakdown of the epithelial barrier. Fucosylated glycans are only one group out of many glycan structures composing the gut glycome. A change in the gut glycome may alter the distribution of microbial species. Therefore, it is possible that alterations in glycan metabolism may contribute to HIV-mediated intestinal damage, microbial translocation, and chronic inflammation.

  • Cell-Surface Glycan-Lectin Interactions Mediate Immunological Functions

    Cell-surface glycan-lectin interactions mediate signals that define cellular processes and immunological functions, many of which are central to HIV infection. The specific structure of a glycan allows it to bind to specific glycan-binding proteins called lectins, leading to activation of downstream signaling pathways. These pathways are critical for a variety of cellular processes and immunological functions:

    • T cells. Galectin-1 induces T cell apoptosis. Galectin-9 induces T-cell receptor (TCR) signaling, while galectin-3 reduces it. Galectin-3 alters T-cell function through interaction with LAG3 and other immune negative checkpoints. Last, the fucosylation of PD-1 impacts its function.
    • NK cells. Siglecs-7 and -9 inhibit NK activity. Galectin-9 impairs NK function/cytotoxicity and cytokine production. Galectin-3 antagonizes NK cell-mediated antitumor immunity
    • B cells. Siglec-6 induces B-cell exhaustion. Galectin-1 is a pre-B cell receptor ligand that induces receptor clustering, leading to efficient B cell differentiation. Galectin-9 suppresses B-cell receptor (BCR) signaling.
    • T-regs. Galectins-1 and -9 can expand T-regs.
    • Myeloid-derived suppressive cells (MDSC). The galectin-9/Tim3 interaction drives the expansion of CD11b+ly6G+ MDSC. Granulocytic MDSCs induce γδ-T cells to produce galectin-1, thus transforming them into immunosuppressive cells. These glycan-lectin interactions represent potential novel targets to enhance immune functionality during HIV infection to either cure HIV or prevent HIV-associated immune dysfunction and the subsequent development of immune dysfunction-associated diseases.

Abdel-Mohsen Lab in the News

Selected Publications

  • Siglec-9 Defines and Restrains a Natural Killer Subpopulation Highly Cytotoxic to HIV-infected Cells.


    Adeniji, O.S., Kuri-Cervantes, L., Yu, C., Xu, Z., Ho, M., Chew, G.M., Shikuma, C., Tomescu, C., George, A.F., Roan, N.R., et al. “Siglec-9 Defines and Restrains a Natural Killer Subpopulation Highly Cytotoxic to HIV-infected Cells.” PLoS Pathog. 2021 Nov 11;17(11):e1010034. doi: 10.1371/journal.ppat.1010034. eCollection 2021 Nov.

  • Non-invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV.


    Giron, L.B., Palmer, C.S., Liu, Q., Yin, X., Papasavvas, E., Sharaf, R., Etemad, B., Damra, M., Goldman, A.R., Tang, H., et al. “Non-invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV.” Nat Commun. 2021 Jun 29;12(1):3922. doi: 10.1038/s41467-021-24077-w.

  • Recommendations for Measuring HIV Reservoir Size in Cure-directed Clinical Trials.


    Abdel-Mohsen, M., Richman, D., Siliciano, R.F., Nussenzweig, M.C., Howell, B.J., Martinez-Picado, J., Chomont, N., Bar, K.J., Yu, X.G., Lichterfeld, M., et al. “Recommendations for Measuring HIV Reservoir Size in Cure-directed Clinical Trials.” Nat Med. 2020 Sep;26(9):1339-1350. doi: 10.1038/s41591-020-1022-1.

  • Sialyl-Lewis X Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy.


    Colomb, F., Giron, L.B., Kuri-Cervantes, L., Adeniji, O.S., Ma, T., Dweep, H., Battivelli, E., Verdin, E., Palmer, C.S., Tateno, H., Kossenkov, A.V., Roan, N.R., Betts, M.R., Abdel-Mohsen, M. “Sialyl-Lewis X Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy.” Cell Rep. 2020 Aug 4;32(5):107991. doi: 10.1016/j.celrep.2020.107991.

  • Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection.


    Giron, L.B., Tanes, C.E., Schleimann, M.H., Engen, P.A., Mattei, L.M., Anzurez, A., Damra, M., Zhang, H., Bittinger, K., Bushman, F., et al. “Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection.” Mucosal Immunol. 2020 Mar 9. doi: 10.1038/s41385-020-0279-5.

View Additional Publications

Continue reading

The Wistar Institute Appoints Former City Solicitor Sozi Tulante to Its Board of Trustees

PHILADELPHIA — (May 26, 2023) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Sozi Tulante to its Board of Trustees. He is currently General Counsel of Form Energy, a Massachusetts-based energy storage technology and manufacturing company.

A respected legal scholar and strategist, Tulante comes to the role with an extensive background in corporate and intellectual property law, policy matters, regulatory issues, and a record of building and leading diverse and sophisticated teams.

“I’m incredibly honored to join the Wistar board and help further its inspiring mission,” said Tulante. “I see it as a crown jewel of Philadelphia. Almost everyone knows someone who has been afflicted with cancer, but few know about the innovative research needed to develop the promising treatments to fight this deadly disease. That all starts here with Wistar research, and that’s something that people can really understand and support.”

Prior to leading Form Energy’s legal, compliance, and ethics functions, Tulante was a litigation partner at the global law firm Dechert LLP, and a professor and fellow at the University of Pennsylvania Carey Law School. From 2016 to 2018, he served as Philadelphia City Solicitor, where he was in charge of all of the City’s legal affairs, advised the Mayor and other City leaders on high-profile and sensitive issues, and managed the 215 lawyers of the Law Department. He is also a former Assistant U.S. Attorney and previously served as a partner at another law firm.

“Sozi’s extensive legal expertise and understanding of intellectual property, along with his familiarity managing complex, high-performing organizations, will be an incredible asset in helping Wistar achieve its mission of producing groundbreaking advances in world health,” said Dario C. Altieri, M.D., Wistar president and CEO, Director of the Ellen and Ronald Caplan Cancer Center, and Robert and Penny Fox Distinguished Professor. “His ability to distill the complexities of an organization and support Wistar’s strategic vision make him an ideal partner.”

Tulante earned his J.D., cum laude, from Harvard Law School, and his B.A., cum laude, from Harvard College. He is originally from the Democratic Republic of Congo before coming to the United States as a refugee and now lives minutes away from Wistar’s headquarters in West Philadelphia with his family.

###

About the Wistar Institute

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century. Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside. wistar.org.

Photo Credit: Diego Radzinsch / © 2023 ALM Global Properties, LLC

Wistar Scientists Successfully Engineer a Goldilocks Construct: Therapeutic Antibody Could Be a Future Medicine to Improve Outcomes for Melanoma

In recent years, multimodal therapies have emerged as a route to treat cancer by delivering different types of treatments together to improve effectiveness. However, the more modalities there are, the more complex the production and effects of these lifesaving treatments can become.

Wistar researchers have engineered a linked molecule that enables a three-modality therapy for treating melanoma. They accomplished this by connecting a cytokine and an antibody—which would ordinarily be administered separately—and then engineering a form that was pro-inflammatory enough to fight the cancer cells but not so inflammatory as to cause complications or reduce survival outcomes, according to a recently published study in Frontiers in Immunology.

“We took aspects of a cancer treatment regimen and tried to simplify that by combining antibody and cytokine together,” said Nicholas Tursi, the lead author on the study and a graduate student researcher in the lab of Dr. David Weiner, executive vice president, director of the Vaccine & Immunotherapy Center, and W.W. Smith Charitable Trust Distinguished Professor at The Wistar Institute. “I focused on engineering an intermediate cytokine that is efficacious but also has an acceptable pro-inflammatory profile—a Goldilocks approach.”

The engineered “Goldilocks” cytokine Tursi and his colleagues, including Dr. Weiner and Dr. Daniel Kulp, Associate professor in Wistar’s Vaccine & Immunotherapy Center, engineered to test their antibody cytokine chimera was called HL2-KOA1, a modified designer version of the T cell growth factor IL-2. This engineered molecule used in a combination therapeutic regimen was effective at promoting survival in a rigorous melanoma model.

“What this suggests is that we could use other antibodies or cytokines to engineer the immune response to further extend efficacy,” said Tursi. He is hopeful that this research will serve as the foundation for developing other antibody cytokine chimeras that work for melanoma and potentially other cancers.

Balancing Act: It’s a Fine Line Between Inflammation and Immunity When Viruses are Involved

Dr. Mohamed Abdel-Mohsen’s Pioneering Research on Siglecs Spotlights Their Role Helping the Immune System Recognize Viral Infections, and as Promising Future Therapy

Dr. Mohamed Abdel-Mohsen and his virology lab at The Wistar Institute review their work with a new class of immune checkpoints called Siglecs to discover the delicate balance between inflammation and immunity. Their findings could drive novel approaches for reducing damaging inflammation due to viral infections during HIV and possibly SARS-CoV-2, as well.

Twenty-five years ago, it was believed that the sequencing of the full human genome would solve all problems and cure all diseases. Today, scientists are discovering that human biology is much more complicated. To better understand cancer and antiviral activity, the field of glycobiology and the human-specific checkpoints known as Siglecs hold the key for richer, more diverse information and the promise of tailored medicines. 

Every immune cell in the human body has many sugar-binding proteins, and some, called negative checkpoint inhibitors, can suppress the immune function of cells. While immunity is important for health, when the immune system reacts too aggressively, it can harm the body — both by triggering excessive inflammation, and by blocking other critical immune functions, both which can make diseases more severe.

In a recently published, in-depth review in the Lancet journal EBioMedicine, Wistar virologist and glycobiologist Mohamed Abdel-Mohsen, Ph.D., looks at how inhibiting and activating immunological switches by manipulating these negative checkpoint inhibitors may both control inflammation and boost immunity during viral infections. 

The quest to learn more about finding the delicate balance between inflammation and immunity in viruses stems from the Abdel-Mohsen lab’s earlier work with both HIV and SARS-CoV-2. Some of the lab’s previous research looked at the relationship between molecules called glycans and siglecs, and how they help diseases evade the immune system. Glycans are a type of sugar molecule that coats cells in the body. In diseased cells, these glycans change to match special receptors, called siglecs, found on the surface of disease-fighting immune cells such as “natural killer” cells. By binding their glycans to these siglec receptors, researchers showed, the infected cells are able to blind the immune cells and avoid detection.

Previous research by Abdel-Mohsen’s lab has shown how interactions between siglecs and glycans play an important role in regulating the immune system when the body is fighting cancer. In their new paper, the researchers looked at the role this process plays in viruses. 

Viruses use several techniques to help them evade immune surveillance, including employing these negative checkpoint inhibitors to change the glycans, or sugars, on the surface of infected cells. Based on their previous discoveries, Abdel-Mohsen’s lab is now working on new treatments that will manipulate these interactions, supercharging the immune system’s ability to target and destroy infected cells.

They recently discovered a new approach that selectively targets and disables these interactions on the surface of HIV-infected cells, effectively making HIV “killable” for the first time. They’re also studying how these glyco-immune checkpoint interactions may help SARS-CoV-2, the virus that causes COVID-19, evade natural killer immune surveillance — and how those interactions could be targeted.

Siglecs are proteins that bind to glycans (sugars) and regulate the signals of immune cells, as well as the body’s inflammatory responses. By learning how to flip the switch to turn ‘on’ the checkpoints that boost immunity, and turn ‘off’ those that reduce inflammation, Wistar scientists hope to better understand and find new approaches for treating cancer, HIV, and potentially even “long COVID.”

The lab is now exploring siglecs to study the tug-of-war that occurs between viruses and the immune systems, with a goal of better understanding how immunological equilibrium is regulated during viral infections. The challenge, Abdel-Mohsen says, is to find ways of precisely managing this immunological equilibrium in a way that enhances the immune response without triggering excessive inflammation or inhibiting other critical immune functions. 

“If we really want to learn the most about human life, we must look at the glycan,” Abdel-Mohsen says. “Understanding glycobiology will help us as a scientific community to better understand the differences between humans and other organisms—as well as the differences that exists between humans. Investments in this next-level, bold science will allow us to achieve advances in precision medicine by developing specific medicines for specific diseases.” 

Coordination/Synthetic Chemist Returns to Cameroon Ready to Train Next Generation of African Scientists on Wistar’s World-Class Analytic Chemistry Techniques

“Our hope is to build a center with the same reflection of Wistar in science and administration.”

In three short months as a Visiting Scholar with The Wistar Institute in Philadelphia, Donatus Bekindaka Eni, BSc., MSc., Ph.D., a lecturer from the University of Buea in the South West Region of Cameroon, experienced a number of career and life-changing firsts. Despite having earned progressive degrees in Biochemistry, Chemistry and then Inorganic Chemistry, it was in a Wistar lab where he first experienced the liquid chromatography-mass spectrometry (LC-MS) and Nuclear Magnetic Resonance (NMR) analytic chemistry instruments. He also witnessed at Wistar the enzyme-linked immunosorbent assays (ELISA) protocol in action. Finally, and perhaps most-eye opening, for the first time in his life, this scientist from tropical Central Africa opened his curtains to a landscape dusted in snow.

A lecturer and published author, Dr. Bekindaka Eni is the third academic from the University of Buea to travel to Wistar as part of a multi-year collaboration between the two research institutions. Wistar is collaborating with the University in the development of Center for Drug Discovery (UB-CeDD) through the Calestous Juma Science Leadership Fellowship awarded to Fidele Ntie-Kang (grant award number: INV-036848 to University of Buea) where scientists study medicinal plants, natural product compounds, and locally synthesized chemical compounds to treat infectious diseases impacting the Sub-Saharan continent, especially on SARS_CoV-2 and HIV.

Dr. Ntie-Kang, who heads the University research center, briefly visited Philadelphia last fall, while University Ph.D. student Chantal Emade Nkwelle spent last September to February for immersive training in many of Wistar’s laboratory techniques. Last fall, Wistar’s Dr. Ian Tietjen, Research Assistant Professor in the Montaner Lab, traveled to Cameroon to help create a strategy that would best apply Wistar’s resources to the University’s needs to expand antiviral and drug discovery abilities.

Now, upon his return to Cameroon, Dr. Bekindaka Eni will train University of Buea scientists and students on the analytical techniques he learned first-hand during his time learning alongside Wistar colleagues.

“We finally have the facilities in Cameroon, and now our hope is to build a center with the same reflection of Wistar in science and administration,” Dr. Bekindaka Eni says. “It may take several years to catch up. After all, Wistar is quite an old institution! The University of Buea shall gain so much from this visit.”

Scientific valorization of traditional knowledge

UB-CeDD will be among the first on the African continent to use computer-aided methods to learn more about herbal compounds passed down through generations by traditional healers. By determining the chemical pharmacophores responsible for the antiviral or antibacterial activity of medicinal plants, scientists can identify the particular isolate in each that is responsible for their healing qualities, predict chemical toxicity, and discover how they function to treat illnesses, such as HIV or SARS-CoV-2, that disproportionately afflict African nations.

“These spiritual doctors have told us what a plant can cure. Now, our research will help us better understand what the different products in that plant consist of, and how they function to cure a particular illness; that is, valorization of traditional knowledge,” Dr. Bekindaka Eni says.

“Scientific valorization of traditional knowledge will be key to helping our people live in good health.”

Superb science

While at Wistar, Dr. Bekindaka Eni spent every possible moment in Wistar’s synthetic labs, especially appreciating the opportunity to monitor reactions using LC-MAs. This analytical chemistry technique combines the physical separation capabilities of liquid chromatography with the mass analysis capabilities of mass spectrometry. In Cameroon, scientists currently use less powerful thin-layer chromatography (TLC) plates to monitor the progress of a reaction or ascertain the effectiveness of purification.

“LC-MS is are one of the things that really captured me,” he said. “I was taught in my B.Sc. and we applied it in both M.Sc. and Ph.D. program on the principle of LC-MS and how it works, but I’d never seen it. At Wistar, I not only got to see it, I used it. It was quite exciting!”

Other highlights of his time with Wistar were the idea exchanges from weekly lab meetings run by Luis J. Montaner, D.V.M., D.Phil., and Joseph Salvino, Ph.D., and time spent in Wistar’s Molecular Screening & Protein Expression Facility managed by Joel Cassel. It was there that Dr. Bekindaka Eni became skilled at using the ELISA protocol, an important diagnostic tool in plant and medicine pathology. The protocol detects the presence of antigens in biological samples and is commonly used to test for antibodies indicating HIV or SARS-CoV-2 infection – a skill he is now eager to pass on to students at the University of Buea.

“The science level at Wistar is superb,” he notes.

Dr. Bekindaka Eni acknowledges that the underlying medicinal synthetic approach for organic synthesis is the same for scientists at both ends of the Wistar/University of Buea exchange, with one great advantage in the States being the use of high-tech equipment.

“In Wistar labs, scientists purify compounds by the use of Biotage®. In Cameroon, we do it manually,” he says. “Other than equipment, however, I was very happy to understand that what we do down there is not too different from what is done at Wistar.”

Regardless of method, the goal in organically synthesizing these products is also the same in either nation, which makes this intercontinental collaboration especially meaningful.

“At Wistar or in Cameroon, we’re all doing this work to save lives.”

Notes From the Field: Seeing Research in Action

More than 1,000 supporters gathered in Fairmont Park for PanCAN PurpleStride Philadelphia 2023 to support the Pancreatic Cancer Action Network (PanCAN). Wistar’s Dr. Rahul Shinde is a PanCAN research grant recipient, and our lab was honored to attend the event and represent the scientific community. People of all ages wore purple to show support with many teams commemorating loved ones lost. I, too, walked in memory of a good friend and uncle who both lost their battles with pancreatic cancer. 

The atmosphere was emotional and inspiring as we heard from a 19-year survivor who described his journey through treatment and recovery. The 5-year survival rate has increased from 10% to 12% in the last few years due in part to PanCAN research and funding. It is their goal to reach a 20% survival rate by 2030.

PanCAN PurpleStride Philadelphia raised over $600,000 with 60 similar events held nationwide. The funds support services for patients and their families, along with research grants to improve early detection and treatment of pancreatic cancer. The Shinde Lab raised more than $1,000 thanks to the support of family and friends. 

Walking among this Philadelphia community of supporters reminds us all of our responsibility to make our research count. PanCAN PurpleStride Philadelphia was a realization of how meaningful our work is. There is heartbreak surrounding pancreatic cancer, but also considerable hope in scientific advancement. 

Notes From the Field Series is written by a member of Wistar’s scientific community and reflects on life, both in and out of a busy biomedical research lab. SK Reiser is a graduate student in the lab of Dr. Rahul Shinde.

After 10 Years as Chief Financial Officer, Joe Trainor Readies for Retirement

It is often said that the measure of a person is in more than just their accomplishments. For Dario Altieri, CEO of The Wistar Institute, trying to sum up the tenure of Joe Trainor, who will be retiring this month as Wistar’s Chief Financial Officer, is not as easy as just rattling off his many achievements.

Under Trainor’s leadership, in the past 7 years, Wistar has doubled its grant funding and tripled its endowment. The effort hasn’t gone unnoticed. In 2022 Joe was recognized by the Philadelphia Business Journal as CFO of the Year for his management of the Wistar finances. He was also recently honored by the University City District, a local organization devoted to addressing economic and quality of life issues in the University City section of Philadelphia, where he served as treasurer for more than 25 years.

With the list of accomplishments out of the way, Altieri followed up with more about who Trainor is: a man of humility and compassion, who supports his team and sees his colleagues as one large family. And true to form, when Trainor took the podium to speak, he was quick to attribute his own success to that of his team. “Without them, I would not accomplish any of this, so thank you.”

As a parting gift, the lifelong Phillies fan received a Philadelphia Phillies T-shirt and a framed photo of the Wistar Institute building signed by his colleagues – a fitting tribute for who he is and what he’s done.

Now, Wistar is on the hunt for a new CFO and has engaged executive search firm Odgers Berndston to identify potential candidates for the role. Interested candidates can contact Kian Ringwood for details or to submit a resume.

GeneOne and Wistar Institute Collaborate to Develop Small Molecule Therapeutics to Protect Humans from Nipah Virus

PHILADELPHIA — (May 10, 2023) — GeneOne Life Science, Inc.(“GeneOne” KOSPI: 011000), a leading biopharmaceutical company specializing in developing nucleic-acid based treatments and novel small-molecule therapeutics, and The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, headquartered in Philadelphia, Pennsylvania, announce a collaboration to identify novel small molecules capable of inhibiting Nipah virus entry into cells and to develop these into preclinical leads for future advancement into global Phase I clinical trials for the treatment and/or post-exposure prophylaxis of Nipah virus infection.

This program anchored at The Wistar Institute is under the direction of Dr. Luis J. Montaner, Kean Family Professor, director of Wistar’s HIV-1 Immunopathogenesis Laboratory and leader of the HIV Research Program, Vaccine & Immunotherapy Center. Montaner’s team has extensive experience in developing small molecule therapies against infectious diseases including HIV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Drug screening and small molecule design will be conducted by Dr. Joseph Salvino, professor in Wistar’s Molecular & Cellular Oncogenesis Program, scientific director of Wistar’s Molecular Screening & Protein Expression Facility, and an industry trained medicinal chemist.

Nipah virus is a zoonotic RNA virus of the genus Henipavirus, that first appeared on farms in Malaysia and Singapore in humans and pigs. Animals or humans exposed to bodily fluids from infected bats, the animal reservoir of Nipah virus, are susceptible to infection. Since 1999, Nipah outbreaks have occurred in other countries of Southeast Asia. Outbreaks of Nipah disease have occurred most frequently in Bangladesh and India since 1999 and have been associated with severe neurological disease as well as high mortality (40-70% death rate). Due to its epidemic potential and insufficient countermeasures against it, the World Health Organization (WHO) has identified Nipah virus as a high priority pathogen for research and development.

“It is an important step for global health that GeneOne and The Wistar Institute are joining forces to develop novel therapies against Nipah virus as a recognized high priority pathogen with future pandemic potential,” said Dr. Montaner.

While there are no approved vaccines or drugs to combat Nipah virus, GeneOne’s Chief Scientific Officer, Dr. Kar Muthumani and colleagues recently demonstrated that a synthetic nucleic acid vaccine they developed could result in an effective anti-Nipah virus cellular and humoral immune response in mice.

Dr. Muthumani said, “We are excited about the immunogenicity of our Nipah vaccine, and now we are pleased to collaborate with The Wistar Institute to develop new small molecule inhibitors to add to our portfolio of countermeasures against Nipah infection. GeneOne has always been an innovator and leader in designing synthetic nucleic acid vaccines against emerging infectious diseases (EIDs) and we expect collaborations such as this to help us add new therapeutics to our portfolio that can be used alone or paired with our vaccines to create stronger countermeasures against EIDs.”

Young K. Park, Chief Executive Officer of GeneOne commented that “In addition to vaccines, there is a critical need for drugs and other therapies that block virus transmission from animals-to-humans and even humans-to-humans. While the goal of this project is to develop drugs that block Nipah virus infection, the methods and tools employed and developed here carry great future potential in creating new drugs against other emerging zoonotic diseases that threaten global health. Moreover, since Nipah virus is a deadly pathogen for which there is currently no vaccine or treatment, GeneOne is eager to contribute our R&D expertise to this collaboration for the health of global citizens.”

###

About GeneOne Life Science Inc.
GeneOne Life Science Inc., headquartered in Seoul, South Korea is an international biotechnology company driven by creativity and innovation and focused on developing nucleic acid encoded vaccines against infectious diseases to address global needs. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases.

VGXI, Inc., GeneOne’s wholly-owned subsidiary located in Texas, is the global leading contract developer and manufacturer (CDMO) for cGMP DNA plasmid manufacture. The company is the leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. VGXI has recently expanded into the manufacture and development of mRNA.

For more information, visit http://www.genels.com and http://www.vgxii.com.

About the Wistar Institute
The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century. Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside. wistar.org

Media Contacts:
GeneOne
Jackie Kwon
+82-2-3458-4032
jakwon@genels.com

The Wistar Institute
Darien Sutton
+1 215-898-3988
dsutton@wistar.org

The Wistar Institute, Pennsylvania Biotechnology Center and Baruch S. Blumberg Institute Forge Strategic Collaboration to Support Regional Biotech Startups

PHILADELPHIA — (MAY 9, 2023) — The Wistar Institute has formed a new strategic collaboration with the Pennsylvania Biotechnology Center (PABC) and the Baruch S. Blumberg Institute to accelerate the advancement of “bench to bedside” biomedical research discoveries in the tri-state region by collectively supporting the seeding, launching and maturation of life science startups.

The Wistar Institute is a Philadelphia-based world leader in discovery science in the areas of cancer, immunology and infectious disease. The PABC is a highly successful nonprofit incubator promoting regional economic development and fostering the development of startup companies in the life sciences. The Blumberg Institute, which manages the PABC, is a nonprofit organization focused on translation research in the life sciences. The two organizations share a campus with their sister institution, the Hepatitis B Foundation, in Doylestown, Pennsylvania.

The PABC and Blumberg Institute will leverage the institute’s scientists and the PABC’s member companies and collaborative entrepreneurial ecosystem with Wistar’s growing pipeline of technologies including NK and T-Cell engaging antibodies, multivalent biologics, small-molecule oncology and immunooncology therapies, cell and gene therapies, and vaccine and diagnostic assets.

As Wistar’s SVP of Business Development and Executive Director of Technology Transfer Heather A. Steinman, Ph.D., MBA, explained, “Through this important collaboration, we see the opportunity to leverage Wistar’s pre-clinical assets in both oncology and infectious diseases with PABC/BSBI’s access to capital, infrastructure and life science sector talent pool to further enhance the innovation ecosystem in the region.”

This collaboration will involve use of B₊labs at Cira Centre, a state-of-the-art incubator in University City, which is managed by the PABC and was conceived, designed and built by Brandywine Realty Trust. Jerry Sweeney, President & CEO of Brandywine Realty Trust, said he is pleased to be furthering the advancement of Philadelphia’s life sciences community.

“This is a welcome reminder of the powerful possibilities that collaborations like this can generate,” Sweeney said. “We’re delighted to provide the physical platform to support the promising startups at B+labs at Cira Centre and look forward to seeing their missions become realized through this dynamic ecosystem.”

Louis P. Kassa III, MPA, Chief Executive Officer of the Hepatitis Foundation, Blumberg Institute and PABC foresees this collaborative model as a prototype to attract talent, new capital and support startups more broadly throughout the Pennsylvania, New Jersey and Delaware life sciences cluster.

“This agreement represents a major new chapter in the PABC’s progress and the evolution of the Blumberg Institute,” Kassa said. “We’re thrilled to be collaborating with The Wistar Institute and we see our relationship growing significantly in the years and months ahead.”

Through their new collaboration, The Wistar Institute and the Pennsylvania Biotechnology Center are planning to co-host a new translational science seminar series, as well as an early-stage life sciences startup how-to seminar series for supporting trainees and entrepreneurial scientists to advance basic research discoveries to clinical therapies.

###

The Wistar Institute
The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century. Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside. wistar.org.

The Pennsylvania Biotechnology Center (PABC)
The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advance biotechnology, maximize synergies among nonprofit scientists and their commercial colleagues, and launch new ideas and discoveries that will make a positive impact. The PABC has nearly 100 member companies and organizations, mostly small to mid-size science, research and pharmaceutical companies. Nearly 50 of those companies operate on the Doylestown campus, which is home to the Hepatitis B Foundation and the Blumberg Institute. The PABC also manages B+labs a Cira Centre, a new incubator in Philadelphia, in partnership with Brandywine Realty Trust. PABC companies have produced numerous FDA-approved drugs and medical devices, and a recent study found that the PABC’s economic impact exceeded $7.3 billion and created more than 1,100 new jobs during 2016-2021.

The Baruch S. Blumberg Institute
An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is one of the nation’s leading centers for translational research in hepatitis B and liver cancer. The Institute supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease and liver cancer in an environment conducive to interaction, collaboration and focus.